Novavax COVID-19 Vaccine Adjuvanted from Canada
Novavax protein-based COVID-19 vaccine with Matrix-M adjuvant, in pre-filled syringes for measured retail doses. Classified as immunological product HTS 3002.15.00.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Saponin adjuvant certificates; hypersensitivity warnings
• 2-8°C storage; 30-day room temp stability post-thaw
• Bulk protein antigen as 3002.30 without adjuvant